Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals, Inc. reported Q2 2026 net revenues of $183,903 thousand, up from $174,414 thousand, with net income of $30,348 thousand versus $31,030 thousand a year earlier. Diluted EPS was $0.67 compared with $0.64. For the first six months, revenue rose to $355,074 thousand from $344,942 thousand, while net income decreased to $36,768 thousand from $56,315 thousand as higher cost of revenues and operating expenses reduced income from operations to $53,359 thousand from $79,477 thousand.
Cash and cash equivalents were $223,614 thousand at June 30, 2026, up from $170,177 thousand at year-end, and short-term investments were $66,509 thousand. Long-term debt, including $345,000 thousand of 2029 Convertible Notes and a $250,000 thousand term loan, was $609,564 thousand net of issuance costs. Net cash provided by operating activities improved to $99,164 thousand in the first half from $70,669 thousand, while share repurchases reached 3,656,720 shares for $74,705 thousand.
The company reached the first BAQSIMI® annual net sales milestone of $175.0 million, triggering a $100.0 million payment to Eli Lilly allocated primarily to BAQSIMI® product rights. BAQSIMI® generated $77,937 thousand of revenue in the first half, while growth in other products and new ipratropium bromide sales offset declines in Primatene MIST® and glucagon revenue. United States operations contributed $331,382 thousand of first-half revenue.
Amphastar Pharmaceuticals reported second-quarter 2026 results with net revenues of $183,903 (in thousands), up 5% from the prior-year quarter. Product performance was mixed, with declines in BAQSIMI, Primatene MIST, Epinephrine and Glucagon offset by growth in other products and the launch of Ipratropium bromide. Gross profit rose to $93,470 (in thousands), expanding gross margin to 50.8% from 49.6%.
Operating expenses increased across selling, general and administrative, and R&D, leading to GAAP net income of $30,348 (in thousands) versus $31,030 a year earlier. Diluted EPS was $0.67, while adjusted non-GAAP net income was $40,759 (in thousands) and adjusted diluted EPS was $0.91. For the first six months of 2026, net revenues were $355,074 (in thousands) and GAAP net income was $36,768 (in thousands), compared with $344,942 and $56,315 (in thousands), respectively, with operating cash flow of $99.2 million.
As of June 30, 2026, the company held cash and cash equivalents of $223,614 (in thousands), short-term investments of $66,509 (in thousands), total assets of $1,743,766 (in thousands), and stockholders’ equity of $768,157 (in thousands). The pipeline includes one ANDA and one biosimilar insulin filed with the FDA targeting markets with a combined size exceeding $1.6 billion, plus additional biosimilar and generic candidates aimed at markets exceeding $3.5 billion and over $1.2 billion, respectively.
Dimensional Fund Advisors LP, a Delaware limited partnership and registered investment adviser, reports beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals common stock, representing 5.2% of the class as of June 30, 2026.
Dimensional has sole voting power over 2,251,660 shares and sole dispositive power over 2,305,107 shares, with no shared voting or dispositive power. The shares are held by client funds for which Dimensional or its subsidiaries provide advisory or management services, and Dimensional disclaims beneficial ownership beyond Section 13(d) reporting. No individual fund’s interest exceeds 5% of the class.
Pierce Anthony T reported acquisition or exercise transactions in this Form 4 filing.
Amphastar Pharmaceuticals director Anthony T. Pierce received equity compensation on July 9, 2026, consisting of 7,886 restricted stock units and 16,646 stock options. All RSUs and options vest on July 9, 2027, with the options exercisable at $19.02 per share and expiring on July 9, 2036. These are grants, not open‑market purchases or sales.
Amphastar Pharmaceuticals, Inc. identifies Anthony T. Pierce as a director and reporting person in an initial insider ownership report. The disclosure shows no equity or derivative holdings and no buy, sell, exercise, or other transactions reported for him in Amphastar securities.
Amphastar Pharmaceuticals, Inc. increased the size of its Board of Directors from ten to eleven members and appointed Anthony Pierce as a Class III director, effective July 9, 2026. He will serve until the company’s 2028 annual meeting of stockholders, or earlier if he departs.
The Board determined that Mr. Pierce is independent under Nasdaq listing standards and noted there are no related-party arrangements or transactions requiring disclosure. His compensation includes an annual cash retainer of $55,000 (pro-rated for his start date) and an initial equity grant split 50% restricted stock units and 50% stock options with an aggregate grant date fair value of $300,000, vesting on the first anniversary of grant, subject to continued service. He will also enter into the company’s standard indemnification agreement.
Amphastar Pharmaceuticals reported that its subsidiary, International Medication Systems, received an FDA Warning Letter on July 2, 2026 for its drug manufacturing facility in South El Monte, California. The letter follows a December 2025 FDA inspection and cites violations of current Good Manufacturing Practice regulations.
The observations relate to investigation procedures, environmental monitoring and handling procedures, and manufacturing equipment. IMS has not been directed to stop or restrict product from the facility or conduct a further recall, and it continues to manufacture while implementing a remediation plan and risk assessment requested by the FDA.
The company is evaluating the impact on its operations and acknowledges there is no assurance the FDA will be satisfied with its response. Until the deficiencies are resolved to the FDA’s satisfaction, additional regulatory or legal action may be taken without further notice.
Amphastar Pharmaceuticals director Richard K. Prins reported new equity awards and prior gifting activity. On June 1, 2026 he received 8,143 shares of Common Stock in the form of restricted stock units, all vesting on June 1, 2027, and a stock option for 17,365 shares at an exercise price of $18.42 per share that also vests on June 1, 2027 and expires on June 1, 2036. A previously reported bona fide gift on August 19, 2024 transferred 1,500 shares of Common Stock. Following the latest transactions, he beneficially owned 37,598 shares as of June 1, 2026 after an account reconciliation noted in the filing.
Amphastar Pharmaceuticals, Inc. director Lee Howard reported routine equity compensation and related tax withholding. On June 1, 2026, he received 8,143 shares of Common Stock in the form of restricted stock units that will fully vest on June 1, 2027, and was granted stock options for 17,365 shares at an exercise price of $18.42 per share, expiring on June 1, 2036. On June 2, 2026, 769 shares of Common Stock were withheld to cover his tax liability from RSU vesting. After these transactions, he directly holds 159,350 shares of Common Stock.
Amphastar Pharmaceuticals director Michael A. Zasloff received new equity awards in the form of stock and options. On June 1, 2026, he was granted 8,143 shares of common stock represented by restricted stock units that vest on June 1, 2027. He also received a stock option for 17,365 shares of common stock at an exercise price of $18.42 per share, expiring on June 1, 2036, with all option shares vesting on June 1, 2027. Following these grants, he directly owns 37,667 shares of Amphastar common stock. These awards represent compensation rather than open-market purchases or sales.